AptarGroup, Inc. designs and manufactures a range of drug delivery, consumer product dispensing, and active material science solutions and services for the pharmaceutical, beauty, personal care, home care, and food and beverage markets. The company operates through Aptar Pharma, Aptar Beauty, and Aptar Closures segments. It also provides pumps for nasal allergy treatments; and metered dose inhaler valves for respiratory ailments, such as asthma and chronic obstructive pulmonary diseases; elastomer for injectable primary packaging components; and active material science solutions. In addition, the company offers dispensing pumps, closures, elastomeric components, aerosol valves, and digital health solutions. It primarily sells its products and services in Asia, Europe, Latin America, and North America. AptarGroup, Inc. was incorporated in 1992 and is headquartered in Crystal Lake, Illinois.

AptarGroup Inc.

Goldman Sachs analyst maintained a Hold rating on Yamato Holdings Co today and set a price target of Yen1,850.00. In a report released yesterday, T...

Goldman Sachs Keeps Their Hold Rating on Yamato Holdings Co (YATRF)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Atricure (ATRC – Research Report), Wave Life Science...

Analysts Offer Insights on Healthcare Companies: Atricure (ATRC), Wave Life Sciences (WVE) and Arcellx Inc (ACLX)

Astron Limited ( ($AU:ATR) ) has issued an update. Astron Limited reported significant progress at its Donald Rare Earth and Mineral Sands Project ...

Astron Advances Donald Rare Earth Project with Major Project Status and Funding Progress

Astron Limited ( ($AU:ATR) ) has shared an announcement. Astron Limited reported a net operating cash outflow of A$1.18 million for the quarter end...

Astron Boosts Cash Reserves via Asset Sales Despite Operating Outflows

Morgan Stanley analyst Angel Castillo maintained a Sell rating on Caterpillar today and set a price target of $400.00. Castillo covers the Industri...

Morgan Stanley Sticks to Its Sell Rating for Caterpillar (CAT)

Yamato Holdings Co ( ($JP:9064) ) has issued an update. Yamato Holdings has announced a major reshuffle of its top management, with current Represe...

Yamato Holdings to Appoint TA-Q-BIN Chief Sakurai as New President in 2026 Leadership Overhaul

Kepler Capital analyst Julian Megias maintained a Buy rating on Atrys Health SA on January 16 and set a price target of €5.00. The company’s shares...

Atrys Health SA (A2T) Gets a Buy from Kepler Capital

Astron Limited ( ($AU:ATR) ) has issued an update. Astron Limited has responded to an ASX query regarding delayed lodgement of Change of Director’s...

Astron Moves to Tighten Compliance After Administrative Lapse on Director Interest Notices

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Atricure (ATRC – Research Report) and Boston Scienti...

Analysts Offer Insights on Healthcare Companies: Atricure (ATRC) and Boston Scientific (BSX)

An update from Atara Biotherapeutics ( ($ATRA) ) is now available. On January 12, 2026, Atara Biotherapeutics reported that the U.S. Food and Drug ...

FDA Rejects Atara’s EBVALLO BLA, Commercial Path Uncertain

Atricure ( ($ATRC) ) has provided an update. On January 9, 2026, AtriCure amended and extended its asset-based revolving credit facility with JPMor...

AtriCure Reports Strong Preliminary 2025 Revenue Growth

Astron Limited ( ($AU:ATR) ) has issued an update. Astron Limited has appointed Catherine Costello as a non-executive director, adding substantial ...

Astron bolsters board with appointment of resource finance veteran Catherine Costello

Stocks are on the move Thursday alongside earnings reports, analyst updates, major deals, and more.


Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!

Atara Biotherapeutics’ ($ATRA) shares glimmered on Thursday morning as investors anticipate the U.S. health watchdog will approve its living cell t...

Atara Biotherapeutics Stock (ATRA) Jumps as FDA Decision on Viral Therapy Nears

In a report released today, Stephen Volkmann from Jefferies maintained a Buy rating on Caterpillar, with a price target of $700.00. According to Ti...

Jefferies Keeps Their Buy Rating on Caterpillar (CAT)

Astron Limited ( ($AU:ATR) ) just unveiled an update. Astron Limited has disclosed a change in director Gerard King’s interests in the company’s se...

Astron Director Increases Indirect Shareholding Through Option Exercise

Astron Limited ( ($AU:ATR) ) has provided an update. Astron Limited has disclosed a change in director George Lloyd’s interest in the company’s sec...

Astron Director George Lloyd Increases Shareholding via Option Exercise

Bank of America Securities analyst Michael Feniger maintained a Buy rating on Caterpillar today and set a price target of $650.00. According to Tip...

Bank of America Securities Reaffirms Their Buy Rating on Caterpillar (CAT)

In a report released on January 5, Sabahat Khan from RBC Capital maintained a Buy rating on AtkinsRealis, with a price target of C$123.00. The comp...

RBC Capital Remains a Buy on AtkinsRealis (SNCAF)

In a report released on January 5, Sabahat Khan from RBC Capital maintained a Hold rating on Caterpillar, with a price target of $587.00. The compa...

RBC Capital Sticks to Its Hold Rating for Caterpillar (CAT)

Companies in the Industrial Goods sector have received a lot of coverage today as analysts weigh in on Astronics (ATRO – Research Report) and Muell...

Current Quarter	$1.24	Next Quarter	$1.23
Current Year	$5.72	Next Year	$5.7
QoQ Growth	-0.8%	YoY Growth	-0.3%
3Y EPS CAGR	+14.9%	Target Price	$160.00
Consensus	Buy	Upside	+28.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ATR	$125.00	+0.14%	336.30K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ATR	$125.00	+0.1%	336.30K
3
4
5
6

ATR

ATR

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get AptarGroup Inc. Data in Excel

Get AptarGroup Inc. Data in Excel